EAST WINDSOR, N.J. — Aurobindo Pharma has launched atazanavir capsules 100 mg, 150 mg, 200 mg and 300 mg upon receiving final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Aurobindo’s Atazanavir capsules are an AB-rated generic equivalent to the reference listed drug REYATAZ.

Atazanavir capsules are indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.

The product has an estimated market size of $324.4 million for the twelve months ending April 2018 according to IQVIA.